More on AMRN
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $14.18 |
|
|||
| Open | $13.98 | ||||
| 52 Wk High | $3.65 | ||||
| 52 Wk Low | $1.24 | ||||
| Day High | $14.23 | ||||
| Day Low | $13.71 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 47,852 | ||||
- Form 10-K AMARIN CORP PLC\UK For: Dec 31
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology
- Amarin Corp. (AMRN) Reports In-Line Q4 EPS
- Form 8-K AMARIN CORP PLC\UK For: Feb 25
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
- Form 4 AMARIN CORP PLC\UK For: Jan 31 Filed by: Ketchum Steven B
- Form 4 AMARIN CORP PLC\UK For: Jan 31 Filed by: Berg Aaron
- Form 4 AMARIN CORP PLC\UK For: Feb 01 Filed by: Provoost Jonathan
Entities mentioned with AMRN
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Jefferies & Co | View Related Stories »
- Definitive Agreement | View Related Stories »
- JPMorgan | View Related Stories »
- AdCom | View Related Stories »
- Cantor Fitzgerald | View Related Stories »
- Options | View Related Stories »
- Show More...
